ArriVent BioPharma, Inc. (AVBP) has released an update.
The Company successfully completed its initial public offering (IPO) on January 30, 2024, with 9,722,222 shares of common stock sold at $18.00 each, resulting in gross proceeds of approximately $175.0 million, excluding underwriting discounts, commissions, and other related expenses.
For further insights into AVBP stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
